glp-1 agonist moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Mechanism of action of GLP-1

The drug is not FDA-approved

Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al

doi: 10.1177/1060028019889064 104 Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial

BPC-157 accelerates ligament remodeling by: Increasing fibroblast density in the ligament substance Enhancing collagen cross-linking for greater tensile strength Reducing the duration of protective splinting/bracing Muscle Strains and Tears Acute muscle injuries (hamstring strains, quadriceps tears, calf strains) benefit from early BPC-157 intervention